SlideShare a Scribd company logo
1 of 26
Download to read offline
Zaragoza, 27th-28th April 2017
Guideline for the elaboration of recommendations
and appropriate use criteria in health
technologies.
Ruth Ubago Pérez
Andalusian Agency for Health Technology
Assessment (AETSA)
PUBLIC HEALTH CONFERENCE
10th anniversary of the Spanish Network of Health Technology Assessment (HTA) Agencies:
Insights for collaborative networking
Towards Patient and public engagement in HTA
BACKGROUND AND CONTEXT
METHODOLOGY
RESULTS
CONCLUSIONS
TABLE OF CONTENTS
BACKGROUND AND CONTEXT (I)
To harmonize procedures as a base for:
 mutual recognition
quality of work
To make those procedures and
methods explicit and public:
assuming a compromise with
transparency
quality in health technology
assessment (HTA )
BACKGROUND AND CONTEXT (II)
Health Technology Assessment as a support to the Decision
Making Process: from EVIDENCE to RECOMENDATIONS.
MAIN STEPS
EVIDENCE SYNTHESIS:
Formulate question
Summary of findings: efficacy/safety
RECOMMENDATION/DECISION
Sintetizar los
principios,
procedimientos y
metodología de la
elaboración de IRE en
el contexto de la Red
BACKGROUND AND CONTEXT (III)
Guideline for the elaboration
and adaptation of rapid health
technology assessment
reports. April, 2016.
Objectives:
To update methods and
processes.
To harmonize procedures.
EVIDENCE SYNTHESIS
Sintetizar los
principios,
procedimientos y
metodología de la
elaboración de IRE en
el contexto de la Red
BACKGROUND AND CONTEXT (IV)
Decision about:
What to do? What to cover?
Should this technology/device be
covered?
Should we stop doing a screening for a
cancer in asymptomatic men? In all
men?
RECOMMENDATION/DECISION
BACKGROUND AND CONTEXT (V)
MAKING RECOMMENDATIONS/DECISION
KEY POINTS
STAKEHOLDER INVOLVEMENT: policy makers, clinicians,
scientific societies and patients.
EXPLICIT AND TRANSPARENT PROCCES TO FORMULATE
A RECOMMENDATION/DECISION.
METHODOLOGY
 COORDINATION GROUP:
Avalia-t and AETSA.
WORKING GROUP: UETS-
ISCIII, Osteba, AQuAS, SCETS,
IACS, UETS Madrid.
1. RECOMMENDATIONS
2. APPROPRIATE USE CRITERIA
3. RECOMMENDATIONS FOR FUTURE
RESEARCH
RESULTS
1. RECOMMENDATIONS
GRADING OF RECOMMENDATIONS, ASSESSMENT,
DEVELOPMENT AND EVALUATION (GRADE) CRITERIAR
PURPOSE:
To inform decisions in the context of:
Clinical recommendations
Coverage decisions
Health system recommendations
WELL ESTABLISHED METHOD
GRADE methodology.
Practical experiences of application of GRADE at various
contexts: World Health Organization, HTA Agencies,
Scientific societies, Cochrane Collaboration.
1. RECOMMENDATIONS
DELIVERABLES SPANISH HTA REPORTS WITH GRADE
RECOMMENDATIONS
GRADING OF RECOMMENDATIONS, ASSESSMENT,
DEVELOPMENT AND EVALUATION (GRADE) CRITERIAR
MAIN STEPS:
PICO question: Setting perspective, Subgroups,
Background.
Assessment of evidence (GRADE methodology)
and judgements. DECIDE project. Evidence to
Decision (EtD) framework.
1. RECOMMENDATIONS
GRADING OF RECOMMENDATIONS, ASSESSMENT,
DEVELOPMENT AND EVALUATION (GRADE) CRITERIAR
DRAWING CONCLUSIONS/RECOMMENDATIONS
COVERAGE DECISIONS:
-Technology not covered.
-Covered only in the context of
research.
-Restricted coverage.
-Full coverage.
Direction and
strength
Justification
Subgroups
Implementation
Monitoring and
evaluation
Research priorities
1. RECOMMENDATIONS
GRADE CRITERIAR
•PANEL COMPOSITION IS A CRUCIAL STEP:
Patients, Policy makers, Clinicians, Scientific societies,
Methodologists.
•ADVANTAGES:
Consistent and transparent method.
How much outcomes are valued by all the stakeholders is
explicitely considered.
•POTENTIAL LIMITATION:
EtD frameworks are complex. Additional resources needed.
1. RECOMMENDATIONS
GRADE CRITERIAR KEY ISSUES
1. RECOMMENDATIONS
2. APPROPRIATE USE CRITERIA.
3. RECOMMENDATIONS FOR FUTURE
RESEARCH.
RESULTS
2. APPROPRIATE USE CRITERIA
PURPOSE:
To assess the
“appropriateness” of medical
procedures or services.
THE RAND/UCLA APPROPRIATENESS METHOD
2. APPROPRIATE USE CRITERIA
DELIVERABLES SPANISH HTA REPORTS WITH
APPROPRIATENESS CRITERIA
THE RAND/UCLA APPROPRIATENESS METHOD
2. APPROPRIATE USE CRITERIA
WHEN TO BE USED
When scientific evidence is not
available or we cannot provide in
depth evidence sufficient to be
applied to the wide range of
patients seen in everyday clinical
practice.
Synthesis of the evidence
List of Indications/Clinical
Scenarios and Definitions
Criteria: Appropriate,
Uncertain, Inappropriate
Expert Panel
rates indications
in Two Rounds
MAIN STEPS
2. APPROPRIATE USE CRITERIA
THE RAND/UCLA APPROPRIATENESS METHOD
Core Panel
KEY ISSUES
ADVANTAGES:
1. Synthesis of published
literature prior to
consensus techniques
incorporated.
2. It allows for both
confidential ratings and
group discussion.
3. Multidisciplinary panel
encourages consensus
from a wider group.
POTENTIAL
LIMITATIONS:
1. Takes great deal of
time from gathering of
the evidence to
multiple rounds of
consensus.
2. Misclassification is
expected.
3. It lacks a clear rating
of the evidence.
2. APPROPRIATE USE CRITERIA
THE RAND/UCLA APPROPRIATENESS METHOD
1. RECOMMENDATIONS
2. APPROPRIATE USE CRITERIA.
3. RECOMMENDATIONS FOR FUTURE
RESEARCH.
RESULTS
3. RESEARCH RECOMMENDATIONS
PURPOSE:
To inform about primary biomedical research
after finding evidence gaps in the published
literature.
3. RESEARCH RECOMMENDATIONS
EUnetHTA framework
Joint Action 2
Work package 7
WHEN TO BE USED
When finding EVIDENCE GAPS after developing HTA report.
“Missing evidence from a body of research that would
potentially answer the questions of decision makers. So final
decision cannot be made until these gaps are covered”.
3. RESEARCH RECOMMENDATIONS
FOR BIOMEDICAL PRIMARY RESEARCH
ADDITIONAL OBSERVATIONAL REAL WORLD DATA AFTER
COVERAGE FOR REINFORMING DECISION MAKING
 We have updated our methods and processes for
developing recommendations and appropriate use
criteria, as well as harmonizing all these procedures.
CONCLUSIONS
Zaragoza, 27th-28th April 2017
Thank you very much
PUBLIC HEALTH CONFERENCE
10th anniversary of the Spanish Network of Health Technology Assessment (HTA) Agencies:
Insights for collaborative networking
Towards Patient and public engagement in HTA
Follow us in
@AETSA_
www.aetsa.org

More Related Content

What's hot

What's hot (20)

Jornadas #PatientInHTA · Gaizka Benguria
Jornadas #PatientInHTA · Gaizka BenguriaJornadas #PatientInHTA · Gaizka Benguria
Jornadas #PatientInHTA · Gaizka Benguria
 
Jornadas #PatientInHTA · Ana Toledo
Jornadas #PatientInHTA · Ana ToledoJornadas #PatientInHTA · Ana Toledo
Jornadas #PatientInHTA · Ana Toledo
 
Jornadas #PatientInHTA · Paloma Casado
Jornadas #PatientInHTA · Paloma CasadoJornadas #PatientInHTA · Paloma Casado
Jornadas #PatientInHTA · Paloma Casado
 
Observatory of Innovation in healthcare management in Catalonia (OIGS)
Observatory of Innovation in healthcare management in Catalonia (OIGS)Observatory of Innovation in healthcare management in Catalonia (OIGS)
Observatory of Innovation in healthcare management in Catalonia (OIGS)
 
Consumer involvement: Patient views on participation in HTA
Consumer involvement: Patient views on participation in HTAConsumer involvement: Patient views on participation in HTA
Consumer involvement: Patient views on participation in HTA
 
Is there patient involvement in HTA? Can patients influence HTA decision making?
Is there patient involvement in HTA? Can patients influence HTA decision making?Is there patient involvement in HTA? Can patients influence HTA decision making?
Is there patient involvement in HTA? Can patients influence HTA decision making?
 
Shared Decision Making in Health in Catalonia
Shared Decision Making in Health in CataloniaShared Decision Making in Health in Catalonia
Shared Decision Making in Health in Catalonia
 
Essencial Project in Catalonia. Avoiding low-value clinical practices
Essencial Project in Catalonia. Avoiding low-value clinical practicesEssencial Project in Catalonia. Avoiding low-value clinical practices
Essencial Project in Catalonia. Avoiding low-value clinical practices
 
Drug development and treatment strategies may go hand in hand.
Drug development and treatment strategies may go hand in hand.Drug development and treatment strategies may go hand in hand.
Drug development and treatment strategies may go hand in hand.
 
Patients’ voice in access decisions
Patients’ voice in access decisionsPatients’ voice in access decisions
Patients’ voice in access decisions
 
Innovations conference 2014 a prof tim shaw defining and prioritising succe...
Innovations conference 2014   a prof tim shaw defining and prioritising succe...Innovations conference 2014   a prof tim shaw defining and prioritising succe...
Innovations conference 2014 a prof tim shaw defining and prioritising succe...
 
Canada’s Orphan Drug Regulatory Framework: What Health Canada is doing now an...
Canada’s Orphan Drug Regulatory Framework: What Health Canada is doing now an...Canada’s Orphan Drug Regulatory Framework: What Health Canada is doing now an...
Canada’s Orphan Drug Regulatory Framework: What Health Canada is doing now an...
 
Tripartite dimension of interaction of patients, regulators and industry (Jan...
Tripartite dimension of interaction of patients, regulators and industry (Jan...Tripartite dimension of interaction of patients, regulators and industry (Jan...
Tripartite dimension of interaction of patients, regulators and industry (Jan...
 
How to communicate scientific and medical information to patients, advocates ...
How to communicate scientific and medical information to patients, advocates ...How to communicate scientific and medical information to patients, advocates ...
How to communicate scientific and medical information to patients, advocates ...
 
Cadth 2015 e6 husereau rwe cadth
Cadth 2015 e6 husereau rwe cadthCadth 2015 e6 husereau rwe cadth
Cadth 2015 e6 husereau rwe cadth
 
IMS Health Clinical Trial Optimization Solutions
IMS Health Clinical Trial Optimization SolutionsIMS Health Clinical Trial Optimization Solutions
IMS Health Clinical Trial Optimization Solutions
 
In Electronic Health Records We Trust - IPPOSI Outcome Report - March 2017
In Electronic Health Records We Trust - IPPOSI Outcome Report - March 2017In Electronic Health Records We Trust - IPPOSI Outcome Report - March 2017
In Electronic Health Records We Trust - IPPOSI Outcome Report - March 2017
 
The role of patients and healthcare providers in translational medicine
The role of patients and healthcare providers in translational medicineThe role of patients and healthcare providers in translational medicine
The role of patients and healthcare providers in translational medicine
 
Formulando recomendaciones implementables
Formulando recomendaciones implementablesFormulando recomendaciones implementables
Formulando recomendaciones implementables
 
"Taking forward Information Sharing"
"Taking forward Information Sharing""Taking forward Information Sharing"
"Taking forward Information Sharing"
 

Similar to Jornadas #PatientInHTA ·Ruth Ubago

AGREE-Reporting-Checklist.pdf
AGREE-Reporting-Checklist.pdfAGREE-Reporting-Checklist.pdf
AGREE-Reporting-Checklist.pdf
HectorVillamarin
 
Aoac practices for microbiological methodology - 2006[2]
Aoac   practices for microbiological methodology - 2006[2]Aoac   practices for microbiological methodology - 2006[2]
Aoac practices for microbiological methodology - 2006[2]
Sc Nscp
 
Clinical practice guidelines
Clinical practice guidelinesClinical practice guidelines
Clinical practice guidelines
abenedicto
 

Similar to Jornadas #PatientInHTA ·Ruth Ubago (20)

MAST: a model for HTA-based assessment of telemedicine applications
MAST: a model for HTA-based assessment of telemedicine applicationsMAST: a model for HTA-based assessment of telemedicine applications
MAST: a model for HTA-based assessment of telemedicine applications
 
Evidence and guidelines COMEP
Evidence and guidelines COMEPEvidence and guidelines COMEP
Evidence and guidelines COMEP
 
Evidence-Based Clinical Practice Guidelines for Medical Staff of Health Care ...
Evidence-Based Clinical Practice Guidelines for Medical Staff of Health Care ...Evidence-Based Clinical Practice Guidelines for Medical Staff of Health Care ...
Evidence-Based Clinical Practice Guidelines for Medical Staff of Health Care ...
 
Care guidelines developing clinical case reporting recommendations – pubrica
Care guidelines developing clinical case reporting recommendations – pubricaCare guidelines developing clinical case reporting recommendations – pubrica
Care guidelines developing clinical case reporting recommendations – pubrica
 
An introduction to conducting a systematic literature review for social scien...
An introduction to conducting a systematic literature review for social scien...An introduction to conducting a systematic literature review for social scien...
An introduction to conducting a systematic literature review for social scien...
 
2021 INTRO TO QUALITY CONTROL.pptx
2021 INTRO TO QUALITY CONTROL.pptx2021 INTRO TO QUALITY CONTROL.pptx
2021 INTRO TO QUALITY CONTROL.pptx
 
Care guidelines developing clinical case reporting recommendations – pubrica
Care guidelines developing clinical case reporting recommendations – pubricaCare guidelines developing clinical case reporting recommendations – pubrica
Care guidelines developing clinical case reporting recommendations – pubrica
 
Evidence-Based Clinical Practice Guidelines for OBSTETRICS AND GYNECOLOGY
Evidence-Based Clinical Practice Guidelines for OBSTETRICS AND GYNECOLOGYEvidence-Based Clinical Practice Guidelines for OBSTETRICS AND GYNECOLOGY
Evidence-Based Clinical Practice Guidelines for OBSTETRICS AND GYNECOLOGY
 
GPC Treatment Switching in Oncology Trials Initiative Overview
GPC Treatment Switching in Oncology Trials Initiative OverviewGPC Treatment Switching in Oncology Trials Initiative Overview
GPC Treatment Switching in Oncology Trials Initiative Overview
 
Webinar 5: Identifying barriers and enablers, and determinants, in practice
Webinar 5: Identifying barriers and enablers, and determinants, in practiceWebinar 5: Identifying barriers and enablers, and determinants, in practice
Webinar 5: Identifying barriers and enablers, and determinants, in practice
 
Treatment Guidelines: A necessity
Treatment Guidelines: A necessityTreatment Guidelines: A necessity
Treatment Guidelines: A necessity
 
AGREE-Reporting-Checklist.pdf
AGREE-Reporting-Checklist.pdfAGREE-Reporting-Checklist.pdf
AGREE-Reporting-Checklist.pdf
 
Board of Governors Meeting Denver, CO
Board of Governors Meeting Denver, COBoard of Governors Meeting Denver, CO
Board of Governors Meeting Denver, CO
 
Clinical Practice Guidelines for Hematology-Oncology in King Saud University ...
Clinical Practice Guidelines for Hematology-Oncology in King Saud University ...Clinical Practice Guidelines for Hematology-Oncology in King Saud University ...
Clinical Practice Guidelines for Hematology-Oncology in King Saud University ...
 
Guidelines to the Preparation of document.pptx
Guidelines to the Preparation of document.pptxGuidelines to the Preparation of document.pptx
Guidelines to the Preparation of document.pptx
 
Agree
AgreeAgree
Agree
 
Aoac practices for microbiological methodology - 2006[2]
Aoac   practices for microbiological methodology - 2006[2]Aoac   practices for microbiological methodology - 2006[2]
Aoac practices for microbiological methodology - 2006[2]
 
Clinical practice guidelines
Clinical practice guidelinesClinical practice guidelines
Clinical practice guidelines
 
Adaptation of evidence-based clinical practice guidelines: the 'Adapted ADAPT...
Adaptation of evidence-based clinical practice guidelines: the 'Adapted ADAPT...Adaptation of evidence-based clinical practice guidelines: the 'Adapted ADAPT...
Adaptation of evidence-based clinical practice guidelines: the 'Adapted ADAPT...
 
Evaluating A Guideline Panic Disorder
Evaluating A Guideline Panic DisorderEvaluating A Guideline Panic Disorder
Evaluating A Guideline Panic Disorder
 

More from Instituto Aragonés de Ciencias de la Salud - IACS

More from Instituto Aragonés de Ciencias de la Salud - IACS (19)

Jornadas #PatientInHTA · Gaizka Benguria
Jornadas #PatientInHTA · Gaizka BenguriaJornadas #PatientInHTA · Gaizka Benguria
Jornadas #PatientInHTA · Gaizka Benguria
 
Jornadas #PatientInHTA · Iñaki Imaz
Jornadas #PatientInHTA · Iñaki ImazJornadas #PatientInHTA · Iñaki Imaz
Jornadas #PatientInHTA · Iñaki Imaz
 
Sesiones Clínicas de Investigación e Innovación 2017. Huesca
Sesiones Clínicas de Investigación e Innovación 2017. HuescaSesiones Clínicas de Investigación e Innovación 2017. Huesca
Sesiones Clínicas de Investigación e Innovación 2017. Huesca
 
Tipos de proyectos que deben ser evaluados por un CEIC
Tipos de proyectos que deben ser evaluados por un CEICTipos de proyectos que deben ser evaluados por un CEIC
Tipos de proyectos que deben ser evaluados por un CEIC
 
Tipos de CEI
Tipos de CEITipos de CEI
Tipos de CEI
 
Marco normativo de los ensayos clínicos. Novedades RD 1090/2015
Marco normativo de los ensayos clínicos. Novedades RD 1090/2015Marco normativo de los ensayos clínicos. Novedades RD 1090/2015
Marco normativo de los ensayos clínicos. Novedades RD 1090/2015
 
Aspectos críticos en un proyecto de investigación clínica. Consideraciones al...
Aspectos críticos en un proyecto de investigación clínica. Consideraciones al...Aspectos críticos en un proyecto de investigación clínica. Consideraciones al...
Aspectos críticos en un proyecto de investigación clínica. Consideraciones al...
 
Comités de ética en la investigación con animales
Comités de ética en la investigación con animalesComités de ética en la investigación con animales
Comités de ética en la investigación con animales
 
Integridad científica
Integridad científicaIntegridad científica
Integridad científica
 
Cómo elaborar una hoja de información para recabar el consentimiento informado
Cómo elaborar una hoja de información para recabar el consentimiento informadoCómo elaborar una hoja de información para recabar el consentimiento informado
Cómo elaborar una hoja de información para recabar el consentimiento informado
 
Qué hace que una investigación sea ética
Qué hace que una investigación sea éticaQué hace que una investigación sea ética
Qué hace que una investigación sea ética
 
Biobancos y colecciones de muestras biologicas
Biobancos y colecciones de muestras biologicasBiobancos y colecciones de muestras biologicas
Biobancos y colecciones de muestras biologicas
 
Aspectos éticos. Novedades RD 1090/2015
Aspectos éticos. Novedades RD 1090/2015Aspectos éticos. Novedades RD 1090/2015
Aspectos éticos. Novedades RD 1090/2015
 
Manejo de datos en investigacion clinica. Aspectos éticos y legales
Manejo de datos en investigacion clinica. Aspectos éticos y legalesManejo de datos en investigacion clinica. Aspectos éticos y legales
Manejo de datos en investigacion clinica. Aspectos éticos y legales
 
Compra Publica de Innovacion: Proyecto Piloto "Descontaminacion barranco de B...
Compra Publica de Innovacion: Proyecto Piloto "Descontaminacion barranco de B...Compra Publica de Innovacion: Proyecto Piloto "Descontaminacion barranco de B...
Compra Publica de Innovacion: Proyecto Piloto "Descontaminacion barranco de B...
 
Compra Pública de Innovacion. Estructura de gobernanza
Compra Pública de Innovacion. Estructura de gobernanzaCompra Pública de Innovacion. Estructura de gobernanza
Compra Pública de Innovacion. Estructura de gobernanza
 
Estrategia de Compra Publica de Innovación en Aragón: Formación
Estrategia de Compra Publica de Innovación en Aragón: FormaciónEstrategia de Compra Publica de Innovación en Aragón: Formación
Estrategia de Compra Publica de Innovación en Aragón: Formación
 
8. Evaluar tecnologías basadas en mHealth. ¿Es posible un marco común de eval...
8. Evaluar tecnologías basadas en mHealth. ¿Es posible un marco común de eval...8. Evaluar tecnologías basadas en mHealth. ¿Es posible un marco común de eval...
8. Evaluar tecnologías basadas en mHealth. ¿Es posible un marco común de eval...
 
7. Análisis coste-efectividad: ¿un umbral para determinar si el coste de una ...
7. Análisis coste-efectividad: ¿un umbral para determinar si el coste de una ...7. Análisis coste-efectividad: ¿un umbral para determinar si el coste de una ...
7. Análisis coste-efectividad: ¿un umbral para determinar si el coste de una ...
 

Recently uploaded

تقرير منظمة الصحة العالمية الخاص بالغذاء د حاتم البيطار.pdf
تقرير منظمة الصحة العالمية الخاص بالغذاء د حاتم البيطار.pdfتقرير منظمة الصحة العالمية الخاص بالغذاء د حاتم البيطار.pdf
تقرير منظمة الصحة العالمية الخاص بالغذاء د حاتم البيطار.pdf
د حاتم البيطار
 
Catheterization Procedure by Anushri Srivastav.pptx
Catheterization Procedure by Anushri Srivastav.pptxCatheterization Procedure by Anushri Srivastav.pptx
Catheterization Procedure by Anushri Srivastav.pptx
AnushriSrivastav
 
Production.pptx\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
Production.pptx\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\Production.pptx\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
Production.pptx\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
DanielOliver74
 

Recently uploaded (20)

PhRMA Vaccines Deck_05-15_2024_FINAL.pptx
PhRMA Vaccines Deck_05-15_2024_FINAL.pptxPhRMA Vaccines Deck_05-15_2024_FINAL.pptx
PhRMA Vaccines Deck_05-15_2024_FINAL.pptx
 
GENETICS and KIDNEY DISEASES /
GENETICS and KIDNEY DISEASES            /GENETICS and KIDNEY DISEASES            /
GENETICS and KIDNEY DISEASES /
 
تقرير منظمة الصحة العالمية الخاص بالغذاء د حاتم البيطار.pdf
تقرير منظمة الصحة العالمية الخاص بالغذاء د حاتم البيطار.pdfتقرير منظمة الصحة العالمية الخاص بالغذاء د حاتم البيطار.pdf
تقرير منظمة الصحة العالمية الخاص بالغذاء د حاتم البيطار.pdf
 
Mike Lowe’s cancer fight lowe strong shirt
Mike Lowe’s cancer fight lowe strong shirtMike Lowe’s cancer fight lowe strong shirt
Mike Lowe’s cancer fight lowe strong shirt
 
Catheterization Procedure by Anushri Srivastav.pptx
Catheterization Procedure by Anushri Srivastav.pptxCatheterization Procedure by Anushri Srivastav.pptx
Catheterization Procedure by Anushri Srivastav.pptx
 
Importance of Diet on Dental Health.docx
Importance of Diet on Dental Health.docxImportance of Diet on Dental Health.docx
Importance of Diet on Dental Health.docx
 
MOTOR NEURON DISEASE - Presentation Neuro
MOTOR NEURON DISEASE - Presentation NeuroMOTOR NEURON DISEASE - Presentation Neuro
MOTOR NEURON DISEASE - Presentation Neuro
 
Leaukemia and it cause sign and symptoms
Leaukemia and it cause sign and symptomsLeaukemia and it cause sign and symptoms
Leaukemia and it cause sign and symptoms
 
Production.pptx\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
Production.pptx\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\Production.pptx\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
Production.pptx\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
 
Boost Your Brain: Discover Natural Herbal Memory Supplements for Enhanced Cog...
Boost Your Brain: Discover Natural Herbal Memory Supplements for Enhanced Cog...Boost Your Brain: Discover Natural Herbal Memory Supplements for Enhanced Cog...
Boost Your Brain: Discover Natural Herbal Memory Supplements for Enhanced Cog...
 
Valle Egypt Illustrates Consequences of Financial Elder Abuse
Valle Egypt Illustrates Consequences of Financial Elder AbuseValle Egypt Illustrates Consequences of Financial Elder Abuse
Valle Egypt Illustrates Consequences of Financial Elder Abuse
 
Case Presentation: CRYPTOCOCCAL MENINGITIS & ORAL CANDIDIASIS –Opportunistic ...
Case Presentation: CRYPTOCOCCAL MENINGITIS & ORAL CANDIDIASIS –Opportunistic ...Case Presentation: CRYPTOCOCCAL MENINGITIS & ORAL CANDIDIASIS –Opportunistic ...
Case Presentation: CRYPTOCOCCAL MENINGITIS & ORAL CANDIDIASIS –Opportunistic ...
 
Session-3-Promoting-Breastfeeding-During-Pregnancy.ppt
Session-3-Promoting-Breastfeeding-During-Pregnancy.pptSession-3-Promoting-Breastfeeding-During-Pregnancy.ppt
Session-3-Promoting-Breastfeeding-During-Pregnancy.ppt
 
Case Presentation: Severe microcytic hypochromic iron deficiency anemia with ...
Case Presentation: Severe microcytic hypochromic iron deficiency anemia with ...Case Presentation: Severe microcytic hypochromic iron deficiency anemia with ...
Case Presentation: Severe microcytic hypochromic iron deficiency anemia with ...
 
Pharmacology and Toxicology Thesis Defense by Slidesgo.pptx
Pharmacology and Toxicology Thesis Defense by Slidesgo.pptxPharmacology and Toxicology Thesis Defense by Slidesgo.pptx
Pharmacology and Toxicology Thesis Defense by Slidesgo.pptx
 
Sugar Medicine_ Natural Homeopathy Remedies for Blood Sugar Management.pdf
Sugar Medicine_ Natural Homeopathy Remedies for Blood Sugar Management.pdfSugar Medicine_ Natural Homeopathy Remedies for Blood Sugar Management.pdf
Sugar Medicine_ Natural Homeopathy Remedies for Blood Sugar Management.pdf
 
Session-5-Birthing-Practices-Breastfeeding (1).ppt
Session-5-Birthing-Practices-Breastfeeding (1).pptSession-5-Birthing-Practices-Breastfeeding (1).ppt
Session-5-Birthing-Practices-Breastfeeding (1).ppt
 
2024 03 Monumental Mistakes in EMS BAD EMS v0.2.pdf
2024 03 Monumental Mistakes in EMS BAD EMS v0.2.pdf2024 03 Monumental Mistakes in EMS BAD EMS v0.2.pdf
2024 03 Monumental Mistakes in EMS BAD EMS v0.2.pdf
 
Giudeline: Adverse event CTCAE version 5.pdf
Giudeline: Adverse event CTCAE version 5.pdfGiudeline: Adverse event CTCAE version 5.pdf
Giudeline: Adverse event CTCAE version 5.pdf
 
Storage_of _Bariquin_Components_in_Storage_Boxes.pptx
Storage_of _Bariquin_Components_in_Storage_Boxes.pptxStorage_of _Bariquin_Components_in_Storage_Boxes.pptx
Storage_of _Bariquin_Components_in_Storage_Boxes.pptx
 

Jornadas #PatientInHTA ·Ruth Ubago

  • 1. Zaragoza, 27th-28th April 2017 Guideline for the elaboration of recommendations and appropriate use criteria in health technologies. Ruth Ubago Pérez Andalusian Agency for Health Technology Assessment (AETSA) PUBLIC HEALTH CONFERENCE 10th anniversary of the Spanish Network of Health Technology Assessment (HTA) Agencies: Insights for collaborative networking Towards Patient and public engagement in HTA
  • 3. BACKGROUND AND CONTEXT (I) To harmonize procedures as a base for:  mutual recognition quality of work To make those procedures and methods explicit and public: assuming a compromise with transparency quality in health technology assessment (HTA )
  • 4. BACKGROUND AND CONTEXT (II) Health Technology Assessment as a support to the Decision Making Process: from EVIDENCE to RECOMENDATIONS. MAIN STEPS EVIDENCE SYNTHESIS: Formulate question Summary of findings: efficacy/safety RECOMMENDATION/DECISION
  • 5. Sintetizar los principios, procedimientos y metodología de la elaboración de IRE en el contexto de la Red BACKGROUND AND CONTEXT (III) Guideline for the elaboration and adaptation of rapid health technology assessment reports. April, 2016. Objectives: To update methods and processes. To harmonize procedures. EVIDENCE SYNTHESIS
  • 6. Sintetizar los principios, procedimientos y metodología de la elaboración de IRE en el contexto de la Red BACKGROUND AND CONTEXT (IV) Decision about: What to do? What to cover? Should this technology/device be covered? Should we stop doing a screening for a cancer in asymptomatic men? In all men? RECOMMENDATION/DECISION
  • 7. BACKGROUND AND CONTEXT (V) MAKING RECOMMENDATIONS/DECISION KEY POINTS STAKEHOLDER INVOLVEMENT: policy makers, clinicians, scientific societies and patients. EXPLICIT AND TRANSPARENT PROCCES TO FORMULATE A RECOMMENDATION/DECISION.
  • 8. METHODOLOGY  COORDINATION GROUP: Avalia-t and AETSA. WORKING GROUP: UETS- ISCIII, Osteba, AQuAS, SCETS, IACS, UETS Madrid.
  • 9. 1. RECOMMENDATIONS 2. APPROPRIATE USE CRITERIA 3. RECOMMENDATIONS FOR FUTURE RESEARCH RESULTS
  • 10. 1. RECOMMENDATIONS GRADING OF RECOMMENDATIONS, ASSESSMENT, DEVELOPMENT AND EVALUATION (GRADE) CRITERIAR PURPOSE: To inform decisions in the context of: Clinical recommendations Coverage decisions Health system recommendations
  • 11. WELL ESTABLISHED METHOD GRADE methodology. Practical experiences of application of GRADE at various contexts: World Health Organization, HTA Agencies, Scientific societies, Cochrane Collaboration. 1. RECOMMENDATIONS DELIVERABLES SPANISH HTA REPORTS WITH GRADE RECOMMENDATIONS GRADING OF RECOMMENDATIONS, ASSESSMENT, DEVELOPMENT AND EVALUATION (GRADE) CRITERIAR
  • 12. MAIN STEPS: PICO question: Setting perspective, Subgroups, Background. Assessment of evidence (GRADE methodology) and judgements. DECIDE project. Evidence to Decision (EtD) framework. 1. RECOMMENDATIONS GRADING OF RECOMMENDATIONS, ASSESSMENT, DEVELOPMENT AND EVALUATION (GRADE) CRITERIAR
  • 13. DRAWING CONCLUSIONS/RECOMMENDATIONS COVERAGE DECISIONS: -Technology not covered. -Covered only in the context of research. -Restricted coverage. -Full coverage. Direction and strength Justification Subgroups Implementation Monitoring and evaluation Research priorities 1. RECOMMENDATIONS GRADE CRITERIAR
  • 14. •PANEL COMPOSITION IS A CRUCIAL STEP: Patients, Policy makers, Clinicians, Scientific societies, Methodologists. •ADVANTAGES: Consistent and transparent method. How much outcomes are valued by all the stakeholders is explicitely considered. •POTENTIAL LIMITATION: EtD frameworks are complex. Additional resources needed. 1. RECOMMENDATIONS GRADE CRITERIAR KEY ISSUES
  • 15. 1. RECOMMENDATIONS 2. APPROPRIATE USE CRITERIA. 3. RECOMMENDATIONS FOR FUTURE RESEARCH. RESULTS
  • 16. 2. APPROPRIATE USE CRITERIA PURPOSE: To assess the “appropriateness” of medical procedures or services. THE RAND/UCLA APPROPRIATENESS METHOD
  • 17. 2. APPROPRIATE USE CRITERIA DELIVERABLES SPANISH HTA REPORTS WITH APPROPRIATENESS CRITERIA
  • 18. THE RAND/UCLA APPROPRIATENESS METHOD 2. APPROPRIATE USE CRITERIA WHEN TO BE USED When scientific evidence is not available or we cannot provide in depth evidence sufficient to be applied to the wide range of patients seen in everyday clinical practice.
  • 19. Synthesis of the evidence List of Indications/Clinical Scenarios and Definitions Criteria: Appropriate, Uncertain, Inappropriate Expert Panel rates indications in Two Rounds MAIN STEPS 2. APPROPRIATE USE CRITERIA THE RAND/UCLA APPROPRIATENESS METHOD Core Panel
  • 20. KEY ISSUES ADVANTAGES: 1. Synthesis of published literature prior to consensus techniques incorporated. 2. It allows for both confidential ratings and group discussion. 3. Multidisciplinary panel encourages consensus from a wider group. POTENTIAL LIMITATIONS: 1. Takes great deal of time from gathering of the evidence to multiple rounds of consensus. 2. Misclassification is expected. 3. It lacks a clear rating of the evidence. 2. APPROPRIATE USE CRITERIA THE RAND/UCLA APPROPRIATENESS METHOD
  • 21. 1. RECOMMENDATIONS 2. APPROPRIATE USE CRITERIA. 3. RECOMMENDATIONS FOR FUTURE RESEARCH. RESULTS
  • 22. 3. RESEARCH RECOMMENDATIONS PURPOSE: To inform about primary biomedical research after finding evidence gaps in the published literature.
  • 23. 3. RESEARCH RECOMMENDATIONS EUnetHTA framework Joint Action 2 Work package 7
  • 24. WHEN TO BE USED When finding EVIDENCE GAPS after developing HTA report. “Missing evidence from a body of research that would potentially answer the questions of decision makers. So final decision cannot be made until these gaps are covered”. 3. RESEARCH RECOMMENDATIONS FOR BIOMEDICAL PRIMARY RESEARCH ADDITIONAL OBSERVATIONAL REAL WORLD DATA AFTER COVERAGE FOR REINFORMING DECISION MAKING
  • 25.  We have updated our methods and processes for developing recommendations and appropriate use criteria, as well as harmonizing all these procedures. CONCLUSIONS
  • 26. Zaragoza, 27th-28th April 2017 Thank you very much PUBLIC HEALTH CONFERENCE 10th anniversary of the Spanish Network of Health Technology Assessment (HTA) Agencies: Insights for collaborative networking Towards Patient and public engagement in HTA Follow us in @AETSA_ www.aetsa.org